Buzz Stocks: Apple Inc., Delta Air Lines, Inc., and TESARO Inc

U.S. stocks appear set to take a breather, as traders' attention turns toward the Fed. Among specific equities in the spotlight are tech titan Apple Inc. (NASDAQ:AAPL), travel concern Delta Air Lines, Inc. (NYSE:DAL), and biotech stock TESARO Inc (NASDAQ:TSRO). Here's a quick look at what's driving AAPL, DAL, and TSRO.

• AAPL is reportedly looking to offset weakening iPhone sales by making a big play in media, building its streaming business with original content, such as television shows and movies. Not everyone is impressed with Apple Inc., though, as RBC this morning lowered its estimates for fourth-quarter and full-year revenue, citing "currency headwinds." The brokerage also adjusted its current-quarter outlook to "reflect incremental production cuts." AAPL is down 0.6% in electronic trading, pulling back after tapping a fresh annual high just south of $120 on Wednesday and closing at $119.75. Analysts are largely optimistic, but with a 14-day Relative Strength Index (RSI) of 73 -- in overbought territory -- the stock may be due for a breather.
  
  
• After initially rising in pre-market trading following the company's earnings report, shares of DAL have reversed course, and are now set to slide 0.9% at the open. The airline revealed weak fourth-quarter profit, but projected better-than-expected unit revenue in the current quarter. On the bright side, Delta Air Lines, Inc. CEO Ed Bastion said this morning that an uptick in consumer confidence since Election Day has already helped the company's earnings numbers. DAL closed last night at $51.44, not far off its December annual highs, and comfortably above the supportive 40-day moving average. But the equity could be in trouble, should analysts meet this morning's report with bearish attention. At present, eight out of 11 firms call the stock at least a "buy," with not a single analyst holding a "sell" opinion.

• TSRO is on pace to drop 3.4% at the open, following news the company received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its chemotherapy-related nausea treatment. TESARO Inc has been barreling higher on the charts since its late-June drug-induced bull gap, and at $145.90, is sitting on a jaw-dropping 274% year-over-year lead. But that hasn't stopped options players betting against the stock -- amid relatively light volumes, anyway. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), TSRO's 10-day put/call volume ratio of 1.25 ranks higher than three-quarters of all readings from the past 12 months. 

Stay on top of overnight news & big morning movers. Sign up now for Schaeffer's Opening View.